PHOENIX--(BUSINESS WIRE)--OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, has extended its intellectual property (IP) portfolio to include an exclusive option to license IP ...
PHOENIX--(BUSINESS WIRE)--OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, today announced the presentation of new preclinical data at the Society for Immunotherapy of Cancer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results